Samsung Biologics

207940.KO

698.51 USD

-0.88

-0.13%

Overview

Last close

698.51 usd

Market cap

49.72B usd

52 week high

761.21 usd

52 week low

522.84 usd

Target price

698.51 usd

Valuation

P/E

N/A

Forward P/E

37.1747

Price/Sales

16.564

Price/Book Value

6.2201

Enterprise Value

50.25B usd

EV/Revenue

14.2981

EV/EBITDA

31.742

Key financials

Revenue TTM

3.51B usd

Gross Profit TTM

1.85B usd

EBITDA TTM

1.59B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

13.13B usd

Net debt

465.98M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.